Literature DB >> 6281837

Anticholinergic activity of imipramine and some analogs at muscarinic receptors of cultured mouse neuroblastoma cells.

R C Petersen, E Richelson.   

Abstract

Imipramine and some of its analogs (trimipramine, 3-chlorimipramine, desipramine, 3-chloro-2-hydroxyimipramine, 2-hydroxyimipramine, and didesmethylimipramine), were assayed for their potencies as antimuscarinic agents by their abilities to antagonize muscarinic receptor-mediated cyclic guanosine monophosphate (GMP) formation by cultured mouse neuroblastoma cells. Equilibrium dissociation constants for these compounds yielded the following rank order of potency at the muscarinic receptor: imipramine greater than trimipramine greater than 3-chlorimipramine greater than desipramine greater than 3-chloro-2-hydroxyimipramine greater than 2-hydroxyimipramine greater than didesmethylimipramine. These results indicate that didesmethylation of the side chain nitrogen or hydroxylation of the ring at the 2-position lead to marked reductions (30-fold and 12-fold, respectively) in antimuscarinic activity of imipramine.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6281837     DOI: 10.1007/bf00430749

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  6 in total

1.  Muscarinic receptor-mediated cyclic GMP formation by cultured nerve cells--ionic dependence and effects of local anesthetics.

Authors:  E Richelson; F G Prendergast; S Divinetz-Romero
Journal:  Biochem Pharmacol       Date:  1978       Impact factor: 5.858

2.  Tricyclic antidepressants block histamine H1 receptors of mouse neuroblastoma cells.

Authors:  E Richelson
Journal:  Nature       Date:  1978-07-13       Impact factor: 49.962

3.  Tricyclic antidepressants and histamine H1 receptors.

Authors:  E Richelson
Journal:  Mayo Clin Proc       Date:  1979-10       Impact factor: 7.616

4.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

5.  Hydroxylated metabolites of tricyclic antidepressants: preclinical assessment of activity.

Authors:  W Z Potter; H M Calil; A A Manian; A P Zavadil; F K Goodwin
Journal:  Biol Psychiatry       Date:  1979-08       Impact factor: 13.382

6.  Structure-activity relationships for the anticholinoceptor action of tricyclic antidepressants.

Authors:  K Shein; S E Smith
Journal:  Br J Pharmacol       Date:  1978-04       Impact factor: 8.739

  6 in total
  7 in total

Review 1.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

2.  Relationship between anti-depressant use and lung cancer survival.

Authors:  Adriana Zingone; Derek Brown; Elise D Bowman; Oscar Vidal; Julien Sage; Joel Neal; Bríd M Ryan
Journal:  Cancer Treat Res Commun       Date:  2017-01-29

3.  A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors.

Authors:  Nadine S Jahchan; Joel T Dudley; Pawel K Mazur; Natasha Flores; Dian Yang; Alec Palmerton; Anne-Flore Zmoos; Dedeepya Vaka; Kim Q T Tran; Margaret Zhou; Karolina Krasinska; Jonathan W Riess; Joel W Neal; Purvesh Khatri; Kwon S Park; Atul J Butte; Julien Sage
Journal:  Cancer Discov       Date:  2013-09-26       Impact factor: 39.397

4.  Antagonism by antidepressants of muscarinic acetylcholine receptors of human brain.

Authors:  E El-Fakahany; E Richelson
Journal:  Br J Pharmacol       Date:  1983-01       Impact factor: 8.739

Review 5.  Rapid eye movement sleep and sleep continuity. Depression and antidepressants.

Authors:  A N Nicholson; P A Pascoe
Journal:  Drugs       Date:  1989       Impact factor: 9.546

Review 6.  Withdrawal phenomena associated with antidepressant and antipsychotic agents.

Authors:  S C Dilsaver
Journal:  Drug Saf       Date:  1994-02       Impact factor: 5.606

7.  Modulation of sleep by trimipramine in man.

Authors:  A N Nicholson; P A Pascoe; C Turner
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.